Safranal-CBD Composition for Lower-Dose Mood Disorder Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing saffron and CBD extracts are not optimally effective in addressing mood disorders, depression, anxiety, stress, and cognitive disorders, with unpredictable biological effects due to the complex interaction of CB1 and CB2 receptors, and there is a need for improved efficacy and reduced dosage requirements.

Innovation Solution

A composition combining a Crocus sativus extract rich in safranal with a Cannabis sativa extract, specifically formulated with a safranal/cannabidiol ratio between 0.03/1000 and 0.03/1, enhancing the entourage effect and improving bioavailability and stability of the molecules.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If saffron extract or CBD extract is administered alone, then the required dosage is high, but the efficacy is insufficient for treating mood disorders, depression, anxiety, and cognitive disorders

Engineering Contradiction:

ImproveefficacyVSAvoiddosage

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent combines saffron extract (containing safranal) and CBD extract into a single composition. This merging of two different active ingredients creates a synergistic effect where the combination produces greater therapeutic efficacy than either substance alone, allowing for reduced dosages while maintaining or improving treatment effectiveness for mood disorders, depression, anxiety, and cognitive disorders.

Inventive Principle:

Principle #5Merging (Combining)

2Adaptability or versatility

If the endocannabinoid system activity is increased or decreased, then receptor activation occurs, but the biological effects are unpredictable due to complex CB1 and CB2 receptor interactions

Engineering Contradiction:

Improvereceptor activationVSAvoidpredictability of biological effects

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent introduces safranal as an intermediary substance that modulates the interaction between CBD and the endocannabinoid system. Safranal acts as a mediator that can enhance or regulate the effects of CBD on CB1 and CB2 receptors, making the biological outcomes more predictable and controllable while still utilizing the adaptive receptor activation mechanism.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Ease of manufacture

If standardized saffron extracts are used according to ISO 3632-2:2010, then manufacturing is simplified, but the safranal content is overestimated by 20 to 50 times

Engineering Contradiction:

ImprovestandardizationVSAvoidsafranal content determination

Core Design Contradiction:

Ease of manufactureVSMeasurement precision

Solution Approach 1:

The patent changes the measurement parameter from UV spectrometry (ISO 3632-2:2010) to HPLC methodology. This parameter change enables precise quantification of actual safranal content, eliminating the 20-50 times overestimation problem while maintaining manufacturing feasibility through established HPLC techniques.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12582687B2Composition based on <i>Crocus sativus </i>and <i>Cannabis sativa</i>

Publication Date: 2026.03.24 ACTIV INSIDE

AI summary

The present invention relates to a composition comprising (i) an extract of Crocus sativus comprising at least safranal, and (ii) an extract of Cannabis sativa comprising cannabidiol (CBD) and uses thereof as a pharmaceutical product, a food supplement, a nutritional product, a cosmetic product, or a liquid suitable for electronic cigarettes.